Impact of Psoralen/UVA-treatment on survival, activation, and immunostimulatory capacity of monocyte-derived dendritic cells

Transplantation

Volumn 85, Issue 5, 2008, Pages 757-766

  Holtick, Udo ^a   Marshall, Scott R ^a   Wang, Xiao Nong ^a   Hilkens, Catharien M U ^a   Dickinson, Anne M ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Dendritic cells; Extracorporeal photopheresis; Graft rejection; Graft versus host disease; PUVA

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4;

APOPTOSIS; ARTICLE; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; ENDOCYTOSIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PUVA; T LYMPHOCYTE; TH2 CELL;

CD40 LIGAND; CELL CULTURE TECHNIQUES; CELL DIVISION; CELL MOVEMENT; CELL SURVIVAL; CYTOKINES; DENDRITIC CELLS; ENDOCYTOSIS; FLOW CYTOMETRY; HUMANS; LYMPHOCYTE ACTIVATION; MONOCYTES; PSORALENS; ULTRAVIOLET RAYS;

EID: 40849092622     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31816650f6     Document Type: Article

References (66)

1. Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 1987; 316: 297.
2. Rook AH, Freundlich B, Jegasothy BV, et al. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial[see comment]. Arch Dermatol 1992; 128: 337.
3. Knobler RM, Graninger W, Lindmaier A, Trautinger F, Smolen JS. Extracorporeal photochemotherapy for the treatment of systemic lupus erythematosus. A pilot study. Arthritis Rheum 1992; 35: 319.
4. Reinisch W, Nahavandi H, Santella R, et al. Extracorporeal photochemotherapy in patients with steroid-dependent Crohn's disease: A prospective pilot study. Aliment Pharmacol Ther 2001; 15: 1313.
5. Greinix HT, Volc-Platzer B, Rabitsch W, et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998; 92: 3098.
6. Smith EP, Sniecinski I, Dagis AC, et al. Extracorporeal photochemotherapy for treatment of drug-resistant graft-vs.-host disease. Biol Blood Marrow Transplant 1998; 4: 27.
7. Messina C, Locatelli F, Lanino E, et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003; 122: 118.
8. Foss FM, DiVenuti GM, Chin K, et al. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: Analysis of response and survival incorporating prognostic factors. Bone Marrow Transplant 2005; 35: 1187.
9. Costanzo-Nordin MR, Hubbell EA, O'Sullivan EJ, et al. Successful treatment of heart transplant rejection with photopheresis. Transplantation 1992; 53: 808.
10. Dall'Amico R, Montini G, Murer L, et al. Benefits of photopheresis in the treatment of heart transplant patients with multiple/refractory rejection. Transplant Proc 1997; 29: 609.
11. Meiser BM, Kur F, Reichenspurner H, et al. Reduction of the incidence of rejection by adjunct immunosuppression with photochemotherapy after heart transplantation. Transplantation 1994; 57: 563.
12. Barr ML, Meiser BM, Eisen HJ, et al. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. N Engl J Med 1998; 339: 1744.
13. Barr ML, Baker CJ, Schenkel FA, et al. Prophylactic photopheresis and chronic rejection: Effects on graft intimal hyperplasia in cardiac transplantation. Clin Transplant 2000; 14: 162.
14. Sunder-Plassman G, Druml W, Steininger R, Honigsmann H, Knobler R. Renal allograft rejection controlled by photopheresis. Lancet 1995; 346: 506.
15. Salerno CT, Park SJ, Kreykes NS, et al. Adjuvant treatment of refractory lung transplant rejection with extracorporeal photopheresis. J Thorac Cardiovasc Surg 1999; 117: 1063.
16. Slovis BS, Loyd JE, King LE, Jr. Photopheresis for chronic rejection of lung allografts. N Engl J Med 1995; 332: 962.
17. Marques MB, Tuncer HH. Photopheresis in solid organ transplant rejection. J Clin Apher 2006; 21: 72.
18. Marshall SR. Technology insight: ECP for the treatment of GvHD - can we offer selective immune control without generalized immunosuppression? Nat Clin Pract Oncol 2006; 3: 302.
19. Suchin KR, Cassin M, Washko R, et al. Extracorporeal photochemotherapy does not suppress T- or B-cell responses to novel or recall antigens. J Am Acad Dermatol 1999; 41: 980.
20. Berger CL, Hanlon D, Kanada D, Girardi M, Edelson RL. Transimmunization, a novel approach for tumor immunotherapy. Transfus Apher Sci 2002; 26: 205.
21. Gorgun G, Miller KB, Foss FM. Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. Blood 2002; 100: 941.
22. Bladon J, Taylor PC. Extracorporeal photopheresis: A focus on apoptosis and cytokines. J Dermatol Sci 2006; 43: 85.
23. Maeda A, Schwarz A, Kernebeck K, et al. Intravenous infusion of syngeneic apoptotic cells by photopheresis induces antigen-specific regulatory T cells. J Immunol 2005; 174: 5968.
24. Lamioni A, Parisi F, Isacchi G, et al. The immunological effects of extracorporeal photopheresis unraveled: Induction of tolerogenic dendritic cells in vitro and regulatory T cells in vivo. Transplantation 2005; 79: 846.
25. Greinix HT, Socie G, Bacigalupo A, et al. Assessing the potential role of photopheresis in hematopoietic stem cell transplant. Bone Marrow Transplant 2006; 38: 265.
26. Peritt D. Potential mechanisms of photopheresis in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12 (1 Suppl 2): 7.
27. Tambur AR, Ortegel JW, Morales A, Klingemann H, Gebel HM, Tharp MD. Extracorporeal photopheresis induces lymphocyte but not monocyte apoptosis. Transplant Proc 2000; 32: 747.
28. Legitimo A, Consolini R, Bencivelli W, Crimaldi G, Migliaccio P, Mosca F. Assessment of 8-methoxypsoralen and ultraviolet a light effects on human stroma generation and function. Acta Haematol 2006; 116: 192.
29. Spisek R, Gasova Z, Bartunkova J. Maturation state of dendritic cells during the extracorporeal photopheresis and its relevance for the treatment of chronic graft-versus-host disease. Transfusion 2006; 46: 55.
30. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179: 1109.
31. Schwarz A, Stander S, Berneburg M, et al. Interleukin-12 suppresses ultraviolet radiation-induced apoptosis by inducing DNA repair. Nat Cell Biol 2002; 4: 26.
32. Heng AE, Sauvezie B, Genestier L, Demeocq F, Dosgilbert A, Deteix P. PUVA apoptotic response in activated and resting human lymphocytes. Transfus Apher Sci 2003; 28: 43.
33. + T cells through IL-12 produced by Listeria-induced macrophages. Science 1993; 260: 547.
34. Reiss Y, Proudfoot AE, Power CA, Campbell JJ, Butcher EC. CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J Exp Med 2001; 194: 1541.
35. Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998; 187: 129.
36. + T lymphocytes primed by myeloid or plasmacytoid dendritic cells. Eur J Immunol 2003; 33: 474.
37. Offner H, Hashim GA, Vandenbark AA. T cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis. Science 1991; 251: 430.
38. Zhang J, Medaer R, Stinissen P, Hafler D, Raus J. MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science 1993; 261: 1451.
39. Rook AH, Prystowsky MB, Cassin M, Boufal M, Lessin SR. Combined therapy for Sezary syndrome with extracorporeal photochemotherapy and low-dose interferon alfa therapy. Clinical, molecular, and immunologic observations. Arch Dermatol 1991; 127: 1535.
40. French LE, Alcindor T, Shapiro M, et al. Identification of amplified clonal T cell populations in the blood of patients with chronic graft-versus-host disease: Positive correlation with response to photopheresis. Bone Marrow Transplant 2002; 30: 509.
41. Berger CL, Perez M, Laroche L, Edelson R. Inhibition of autoimmune disease in a murine model of systemic lupus erythematosus induced by exposure to syngeneic photoinactivated lymphocytes. J Invest Dermatol 1990; 94: 52.
42. Girardi M, Herreid P, Tigelaar RE. Specific suppression of lupus-like graft-versus-host disease using extracorporeal photochemical attenuation of effector lymphocytes. J Invest Dermatol 1995; 104: 177.
43. Berger CL, Xu AL, Hanlon D, et al. Induction of human tumor-loaded dendritic cells. Int J Cancer 2001; 91: 438.
44. Legitimo A, Consolini R, Failli A, et al. In vitro treatment of monocytes with 8-methoxypsolaren and ultraviolet A light induces dendritic cells with a tolerogenic phenotype. Clin Exp Immunol 2007.
45. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F. Kinetics of dendritic cell activation: Impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 2000; 1: 311.
46. Watanabe S, Kagamu H, Yoshizawa H, et al. The duration of signaling through CD40 directs biological ability of dendritic cells to induce antitumor immunity. J Immunol 2003; 171: 5828.
47. Camporeale A, Boni A, Iezzi G, et al. Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes. Cancer Res 2003; 63: 3688.
48. + T cell-mediated acute graft-versus-host disease. J Clin Invest 2002; 109: 1335.
49. McKenna KE, Whittaker S, Rhodes LE, et al. Evidence-based practice of photopheresis 1987-2001: A report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group. Br J Dermatol 2006; 154: 7.
50. Kim S, Elkon KB, Ma X. Transcriptional suppression of interleukin-12 gene expression following phagocytosis of apoptotic cells. Immunity 2004; 21: 643.
51. Schwarz A, Maeda A, Kernebeck K, van Steeg H, Beissert S, Schwarz T. Prevention of UV radiation-induced immunosuppression by IL-12 is dependent on DNA repair. J Exp Med 2005; 201: 173.
52. Rescigno M, Martino M, Sutherland CL, Gold MR, Ricciardi-Castagnoli P. Dendritic cell survival and maturation are regulated by different signaling pathways. J Exp Med 1998; 188: 2175.
53. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434.
54. Seung E, Iwakoshi N, Woda BA, et al. Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 antibody: Absence of graft-versus-host disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in isletallografted NOD/Lt mice. Blood 2000; 95: 2175.
55. Masunaga T, Yamashita K, Sakihama H, et al. Dimeric but not monomeric soluble CD40 prolongs allograft survival and generates regulatory T cells that inhibit CTL function. Transplantation 2005; 80: 1614.
56. Kalinski P, Schuitemaker JH, Hilkens CM, Wierenga EA, Kapsenberg ML. Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: Decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. J Immunol 1999; 162: 3231.
57. Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001; 106: 263.
58. Kalinski P, Hilkens CM, Snijders A, Snijdewint FG, Kapsenberg ML. IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J Immunol 1997; 159: 28.
59. Fischbein MP, Yun J, Laks H, et al. Regulated interleukin-10 expression prevents chronic rejection of transplanted hearts. J Thorac Cardiovasc Surg 2003; 126: 216.
60. Zhou X, Schmidtke P, Zepp F, Meyer CU. Boosting interleukin-10 production: Therapeutic effects and mechanisms. Curr Drug Targets Immune Endocr Metabol Disord 2005; 5: 465.
61. Stammberger U, Bilici M, Gugger M, et al. Prolonged amelioration of acute lung allograft rejection by overexpression of human interleukin-10 under control of a long acting ubiquitin C promoter in rats. J Heart Lung Transplant 2006; 25: 1474.
62. Davidson C, Verma ND, Robinson CM, et al. IL-13 prolongs allograft survival: Association with inhibition of macrophage cytokine activation. Transpl Immunol 2007; 17: 178.
63. Obara H, Nagasaki K, Hsieh CL, et al. IFN-gamma, produced by NK cells that infiltrate liver allografts early after transplantation, links the innate and adaptive immune responses. Am J Transplant 2005; 5: 2094.
64. Klosner G, Trautinger F, Knobler R, Neuner P. Treatment of peripheral blood mononuclear cells with 8-methoxypsoralen plus ultraviolet A radiation induces a shift in cytokine expression from a Th1 to a Th2 response. J Invest Dermatol 2001; 116: 459.
65. Craciun LI, Stordeur P, Schandene L, et al. Increased production of interleukin-10 and interleukin-1 receptor antagonist after extracorporeal photochemotherapy in chronic graft-versus-host disease. Transplantation 2002; 74: 995.
66. Liu J, Anderson BE, Robert ME, et al. Selective T-cell subset ablation demonstrates a role for T1 and T2 cells in ongoing acute graft-versus-host disease: A model system for the reversal of disease. Blood 2001; 98: 3367.